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Abstract
Background: Maternal obesity is associated with increased risks of adverse pregnancy-related complications and
outcomes for both mothers and infants. Overweight and obese women have an increased risk of pregnancy-
induced hypertension, preeclampsia and gestational diabetes mellitus (GDM). Infant Body Mass index (BMI) and the
risk of obesity in adulthood are related to maternal gestational weight gain (GWG). Preventive lifestyle and dietary
interventions are time-consuming and do not always reduce GWG or the risk of maternal pregnancy complications.
Recent research has indicated that the gut microbiota may play a significant role in the development of obesity.
Some studies have indicated that the daily consumption of probiotics may reduce the risk of preeclampsia,
maintain serum insulin levels and reduce the frequency of GDM in pregnant women. The aims of this study are to
investigate whether daily probiotic supplements in obese women during pregnancy can limit gestational weight
gain, improve glucose homeostasis and thereby improve maternal, fetal and infant health outcomes.
Methods: A pilot study including 50 obese pregnant nulliparous women with a prepregnancy BMI of between 30
and 35 kg/m2 will be randomized to receive daily probiotics (four capsules of Vivomixx®; total of 450 billion CFU/
day, including eight probiotic bacterial strains) or placebo from gestational age 14–20 weeks until delivery. The
infants will be followed until 9 months of age. The women will be monitored by weight, blood, fecal, vaginal and
urine samples, diet questionnaires and hospital record review. Primary outcomes are: maternal weight gain,
glycated hemoglobin (HbA1c) level and changes in glucose concentration measured during an oral glucose
tolerance test. Secondary outcomes are: microbiota and inflammatory markers in mother and child, pregnancy
complications, pregnancy outcomes, physical activity and the body composition of the neonate.
Discussion: We expect to find alterations in the metabolic profiles, microbiota and possibly pregnancy outcomes.
From a clinical point of view the effects of Vivomixx® could control weight gain and reduce complications during
pregnancy by inducing changes in the gut microbiota. Furthermore, this intervention during pregnancy could
influence the infant’s microbiota, which could have important implications for infant development and health.
Trial registration: ClincalTrials.gov Identifier: NCT02508844, registered on 11 May 2015.
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Background
Maternal obesity has become highly prevalent worldwide
and is associated with an increased risk of maternal
pregnancy-related complications and an increased risk
of adverse pregnancy outcomes [1]. Women who are
overweight or obese during pregnancy and childbirth, as
measured by a high maternal Body Mass Index (BMI),
have an increased risk of pregnancy-induced hyperten-
sion, preeclampsia and gestational diabetes mellitus
(GDM) [2]. Maternal obesity may adversely affect the
fetus and fetal growth in the initial stages of life, the risk
of pregnancy complications, as well as the child’s later
development [3]. Maternal GDM increases the risk of
excessive adiposity in the fetus, macrosomia (a birth
weight of over 4000 g) and neonatal hypoglycemia [4, 5].
In the long term, maternal GDM is associated with an
increased risk of obesity as well as metabolic (type 2 dia-
betes) and cardiovascular disease in both mother and child
[6]. Over the past three decades, the incidence of obesity
among children and adolescents has increased radically
[7]. Gestational weight gain (GWG) is related to BMI in
childhood and to the risk of obesity in adulthood [8]. The
newborn’s fat mass increases by every kilogram of GWG
[9], but in obese women adherence to GWG recommen-
dations do not prevent high birth weights [10]. In obese
pregnant women, a randomized study has shown that
physical activity intervention assessed by pedometer
reduces GWG compared with controls, but also that the
recommended GWG of maximal 9 kg was only met in
about 50 % of the women [11].
Most studies addressing the prevention of GDM and
excessive GWG among overweight and obese pregnant
women have been restricted to lifestyle interventions,
which often result in either no or modest reduction in
GWG [12].
Probiotics are live microorganisms which, when admin-
istered in adequate amounts, may confer a health benefit
on the host [13]. Probiotics consist of individual or
multiple live bacterial species (such as lactobacilli and
bifidobacteria) that during intake can alter the gut micro-
biota [14]. Recent research has indicated that the gut
microbiota may play a significant role in the development
of obesity, obesity-associated inflammation and insulin
resistance [15]. Experiments with mice have shown that
the composition of the bacteria in the gut may affect
weight regulation [16]. In other animal models, associa-
tions have been found between changes in gut flora and
obesity, insulin resistance and diabetes [17]. Modulation
of the gut microbiota early in life has thus attracted inter-
est since differences in its compositional development
may predict the risk of overweight in the offspring [18].
The etiology of the development of obesity is not clearly
elucidated, but a complex interaction between genetic, epi-
genetic and social factors is likely. The prevalence of
obesity has been rising faster than can be explained by bio-
logical variation, indicating that genetics is not the only
cause [19]. In addition, there is small but consistent
evidence showing that the daily consumption of probiotics
may reduce the risk of preeclampsia [20], maintain serum
insulin levels [21] and reduce the frequency of GDM [22]
in pregnant women. Vivomixx® consists of eight strains of
freeze-dried probiotic bacteria. The product contains the
same mixture of bacteria as the product VSL#3 and some
studies demonstrate that VSL#3 may normalize gut
permeability and barrier function, which is associated with
beneficial anti-inflammatory and immunomodulatory
properties [23, 24]. A new study on mice has demonstrated
that the administration of VSL#3 can prevent and treat
obesity and diabetes in several mouse models and suppress
body weight gain and insulin resistance via modulation of
the gut microbiota [25]. VSL#3 promotes release of the
hormone glucagon-like peptide 1 (GLP-1) resulting in re-
duced food intake and improved glucose tolerance. The
VSL#3-induced changes are associated with an increase in
the levels of a short chain fatty acid (SCFA), butyrate [24].
Butyrate stimulates the release of GLP-1 from intestinal L-
cells thereby providing a plausible mechanism for VSL#3’s
action. Promising results have also been shown in humans.
A randomized controlled study by Rajkumar et al. in 2014
among 60 overweight (BMI >25) but otherwise healthy
adults showed a significant reduction in total cholesterol,
triglycerides, low density lipoproteins (LDL) and very-low-
density lipoproteins (VLDL) (P < 0.05) after 6 weeks of
VSL#3 treatment. They also found improved insulin sensi-
tivity (P < 0.01), decreased C-reactive protein (CRP), and a
favorable effect on the composition of gut microbiota [26].
A randomized study by Alisi et al. in 2014 examined the
beneficial effects of VSL#3 in 48 obese children with nonal-
coholic steatohepatitis. After 4 months of treatment, BMI
was significantly reduced and GLP-1 secretion increased in
the VSL#3-supplemented children compared to the pla-
cebo group (P < 0.001) [27]. Moreover, VSL#3 has also
been tested in a small interventional study among 27
healthy pregnant women by Vitali et al. in 2012 in order to
investigate changes in the composition of the vaginal
microbiota and cytokine secretion. VSL#3 was adminis-
tered during the last trimester of pregnancy and was asso-
ciated with modulation of the vaginal microbiota and
cytokine secretion [28]. None of the studies [25–27] re-
ported side effects related to the treatment with VSL#3. As
accumulating evidence indicates that the gut microbiota
plays a significant role in obesity and because the “ideal”
composition of the gut microbiota remains poorly under-
stood, modulation of the gut microbiota composition rep-
resents a potentially attractive treatment option against
excessive GWG and adverse outcomes for mothers and
infant. Dietary supplements in the form of probiotics could
potentially be beneficial for controlling weight gain in
Halkjaer et al. Trials  (2016) 17:491 Page 2 of 9
pregnancy by inducing changes in the gut microbiota and
could also affect the infant’s microbiota, which may have
important implications for infant development and health.
Aims and hypotheses
In a pilot study of 50 obese pregnant women, we aim to
investigate if the probiotic Vivomixx® can affect gesta-
tional weight gain, glycated hemoglobin (HbA1c) level
and reduce impairment of glucose tolerance at gesta-
tional weeks 27–30, compared to weeks 14–20, in obese
pregnant women. The aim of conducting an initial pilot
study (n = 50) is to clarify feasibility and compliance and
to estimate parameters, such as the standard deviation,
which will be used in a sample size calculation for a full-
scale trial. The study will also give an estimate of the
proportion of eligible women who are willing to partici-
pate, of participants who drop out of the trial and of par-
ticipants who comply with their allocated intervention.
Secondary aims are:
 To examine changes in microbiota and inflammatory
markers in mother and child (in fecal samples)
 To examine changes in vaginal microbiological
profile and frequency of urinary tract infections
(including group B streptococcus infections)
 To examine changes in concentrations of lipids and
inflammatory markers (maternal blood sample)
 To assess if the intervention reduces the risk of
complications during pregnancy and at birth –
including GDM, preeclampsia, gestational
hypertension, change in the mode of delivery,
gestational age, macrosomia (birth weight of over
4000 g) and large- and small-for-gestational-age
infants
 To examine the impact of the intervention on diet,
physical activity levels and breastfeeding
 To examine differences in the neonatal outcome –
weight, z-score, Apgar score after 5 min, umbilical
cord pH, and the risk of early neonatal transfer to
the neonatal intensive care unit
 To assess the child’s weight gain and body
composition until 9 months of age (dual-energy X-
ray absorptiometry (DEXA) scanning (at birth) and
skin-fold measurements thereafter)
Methods
Study design
In this single-center, double-blind, randomized, placebo-
controlled pilot study, 25 obese pregnant women will be
treated with probiotics and 25 will be treated with pla-
cebo. Included pregnant women will receive two capsules
of the probiotic mixture Vivomixx® or placebo twice daily
from gestational weeks 14–20 until delivery. Examination
including blood, urine, vaginal and fecal sampling will be
performed at gestational weeks 14–20 (baseline), 27–30
and 36–37 in all study participants. Data on infants are
collected at birth, 18–72 h after birth, and after 3, 6 and
9 months. An overview of study visits is illustrated in
Fig. 1. The study will connect to the study “The Treatment
of Obese Pregnant Women (TOP)” [11] at Hvidovre
University Hospital, with the objective to compare data.
Recruitment of participants
The women will be identified when they are booked
for the initial nuchal translucency ultrasound scan at
Copenhagen University Hospital Hvidovre. Written
consent will also be obtained from obese pregnant
women who do not wish to participate in order to
compare data from their pregnancy outcome with that
of the study participants.
Inclusion criteria
 Aged over 18 years
 Prepregnancy BMI ≥30 and <35 kg/m2
 Nulliparous singleton pregnancy
 Ability to read and speak Danish
 Normal ultrasound scan of the fetus at gestational
age 12–14 weeks
 Oral glucose tolerance test (OGTT) at gestational
age 14–20 weeks
Exclusion criteria
 Pregnancy at over 20 weeks’ gestation at recruitment
 Pregestational diabetes or other serious diseases
 Multiple pregnancy
 Previous bariatric surgery
 Ingestion of probiotics more than 1 month before
the inclusion or ingestion of probiotics other than
the study probiotics
 Alcohol or drug abuse
Randomization procedure
The women are randomized to Vivomixx® or placebo
in a 1:1 ratio. The capsules are packed in numbered
bags with either Vivomixx® or placebo content at the
hospital pharmacy (Region Hovedstadens Apotek,
Klinisk Farmaceutisk Service, Kettegaard Alle 30, 2650
Hvidovre). The randomization is done by computer
software in blocks of 4. Both capsules are identical in
appearance and packages. The identity of the capsules
is unknown to participants, researchers and primary
investigators.
Study agent
Vivomixx® (manufactured by Mendes SA, Lugano,
Switzerland) is a probiotic mixture which contains the
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following strains: Streptococcus thermophilus DSM 24731,
bifidobacteria (Bifidobacterium breve DSM 24732, Bifido-
bacterium longum DSM 24736, Bifidobacterium infantis
DSM 24737) and lactobacilli (Lactobacillus acidophilus
DSM 24735, Lactobacillus plantarum DSM 24730,
Lactobacillus paracasei DSM 24733, Lactobacillus del-
brueckii subsp. bulgaricus DSM 24734) and is formu-
lated in vegetable capsules containing 112 billion
lyophilized bacteria. Women allocated to the placebo
group will receive capsules containing microcrystalline
cellulose, magnesium stearate and silicon dioxide.
Capsules are stored at 2 to 8 °C prior to distribution.
The participants are also instructed to refrigerate the
capsules at home. Both written and verbal instruc-
tions regarding use and storage of capsules are
provided.
Data handling and record keeping
Case Report Forms (CRF) will be used to record data for
all participants, and data will be double-entered on an
electronic database to secure its validity. Questions in
the CRF collect a range of data including effect modifiers
(antibiotics), outcome data and adverse events. The
research staff is the same two people throughout the
study to standardize the data collection procedure.
Assessment of primary outcomes
Gestational weight gain is the primary outcome. Mater-
nal weight gain is defined as weight at gestational age
36–37 weeks minus self-reported prepregnancy weight.
All women are weighed at the same scale at every study
visit, wearing light clothing and no shoes (Seca digital
scales, Seca, Hamburg, Germany). GWG values are cal-
culated as the difference between the mother’s prepreg-
nancy weight and her weight at 36–37 weeks of
gestation.
The other primary outcome is the change in mater-
nal fasting glucose from weeks 14–20 (preinterven-
tion) to weeks 27–30 between probiotic and placebo
groups. GDM outcomes are assessed at 14–20 and
27–30 weeks’ gestation by a three-time-point 75-g
OGTT. Preparation for the test includes a 10–13-h
pretest fast with instructions to avoid smoking and
chewing gum during this time and during the test.
Tap water intake should be limited to two glasses
(300 ml) and exercise on the morning of the test
Fig. 1 Study flow chart of the pilot study
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should be avoided. Participants remain in a resting
state during the test.
Measurements are listed in Table 1.
Other measures
Questionnaires
Participants in the study will complete a questionnaire
at the time of inclusion about demographic data
including smoking history, educational level, and data
about prepregnancy physical activity. Women who
decline to participate in the study will be asked to
complete the same questionnaire. Dietary and supple-
mental intake will be measured by a validated Food
Frequency Questionnaire (FFQ) at the time of inclu-
sion and before delivery (weeks 36–37) [29].
Physical activity
Participants will be instructed in using a validated
pedometer: a Yamax Digiwalker CW-700/750 (Yamax
Corporation, Tokyo, Japan) [30] three times during
pregnancy to monitor physical activity. Daily step
counts will be registered on seven consecutive days at
inclusion (baseline) and in weeks 27–30 and weeks
36–37 of gestation, and the women will also be asked
about swimming and cycling during pregnancy.
Fecal samples
Fecal samples are collected at home and sent by mail
and then frozen at −80 °C. Bacterial deoxyribonucleic
acid (DNA) will be extracted from the fecal samples
using the PowerSoil DNA Isolation Kit, which has been
found to be suitable in similar clinical studies [31]. The
universal bacterial primers S-D-Bact-0341-b-S-17 and S-
D-Bact-0785-a-A-21, affixed to Illumina adapters, will be
used for the amplification of the 16S V3-V4 region. This
primer couple has been found to be appropriate to
monitor microbe diversity [32].
Urine samples
Urine samples are collected at home by the participant
on the morning that they attend the study visit. The
sample should be taken from first midstream urine in
the morning after overnight fasting. At the hospital 5 ml
are frozen at −80 °C in sterile tubes (Falcon 15-ml poly-
propylene) containing 50 μl NaN3.
Table 1 Maternal and neonatal/infant primary and secondary outcomes
Measurement Inclusion/randomization
(14–20 weeks)
27–30
weeks
36–37
weeks
Delivery 1–3 days after
delivery
3 months after
delivery
6 months after
delivery
9 months after
delivery
Baseline questionnaire X
Diet questionnaire X X
Weight (pregnant/mother) X X X X X X X
Blood sample (pregnant/
mother)
X X X X X X
Blood pressure X X X
Fecal sample (pregnant/mother) X X X X X X X
Urine sample + vaginal swab X X X
Pedometer X X X
OGTT X X
Fecal sample – infant X X X X
Urine sample – infant X X X X
Newborn – umbilical cord
blood sample
X
DEXA scanning X
Breast milk sample X X X X
Newborn/child physical
examination and
anthropometric data
X X X X
Question about urinary
tract infections
X X X
Question about colic symptoms,
breastfeeding, allergy and atopic
dermatitis
X X X
DEXA dual-energy X-ray absorptiometry, OGTT oral glucose tolerance test
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Vaginal samples
Vaginal samples are collected at home using an eSwab
and sent by mail. eSwab is a liquid-based multipurpose
collection and transport system that maintains the via-
bility of aerobic, anaerobic and fastidious bacteria for up
to 48 h.
Blood samples
Blood samples will be taken at every study visit during
the study period. They will be analyzed for concentra-
tions of i.a. lipids and lipoproteins (high-density lipopro-
tein (HDL), low-density lipoprotein (LDL) and total
cholesterol), inflammatory markers (CRP, interleukin
(IL)-18, IL-6 and tumor necrosis factor alpha (TNF-α)),
Glycated hemoglobin (HbA1c) level, homocysteine,
GLP-1 and BDNF (brain-derived neurotrophic factor).
At study visits during pregnancy the participants will be
fasting.
Breast milk samples
Breast milk samples will be collected at all study visits
after birth. Samples are taken on the day of the study
visit. The samples are frozen at −80 °C at the hospital.
Hospital chart review
Hospital records directly related to pregnancy and delivery
will be reviewed. Pregnancy complications and mode of
delivery will be extracted from hospital files and validated
using the Danish national guidelines. GDM will be defined
according to the International Association of Diabetes in
Pregnancy Study Group (IADPSG) criteria, to be able to
compare results from this study with other international
studies. Preeclampsia will be defined as proteinuria (dip-
stick, greater than 1+ protein) and persistently elevated
blood pressure greater than 140/90 mmHg on more than
one occasion. Gestational hypertension is diagnosed using
the same criteria but without proteinuria. Macrosomia is
defined as birthweight of 4000 g or greater. The z-score of
the newborn will be calculated (deviation from the ex-
pected weight corrected for gestational age and sex) [33].
Apgar scores and eventual delivery complications will also
be registered. All admissions to the neonatal care unit will
also be recorded along with diagnosis for admission.
Women who choose to withdraw from the study will be
asked if they will allow review of their hospital records for
the purpose of comparing “drop-outs” with women who
remain in the study.
DEXA scanning and infant examination
A DEXA scan is conducted before 72 h post birth for
the newborn and the parents. The method is validated in
the newborn [34]. The infants will be weighed recum-
bent (Seca 727, digital baby scales, Seca, Hamburg,
Germany), and their length and head circumference are
measured with a measuring tape according to World
Health Organization guidelines. Abdominal circumfer-
ence is measured at the umbilical level in the supine
position during mid-expiration. Newborn anthropomet-
ric measurements are collected from their birth chart.
Subject compliance monitoring and capsule viability
Patient compliance will be monitored by requesting the
patients to return all unused capsules at the visit at
gestational weeks 27–30 and at follow-up after delivery.
The patient should consume at least 80 % of the study
medication during the study period. Fecal samples are
collected from participants and it will be proven whether
the probiotic bacteria are established in the gut of the
intervention group by using strain-specific primers.
Samples of capsules returned from the participants will
be tested to ensure that the capsules have maintained
their viability.
Safety and adverse event monitoring
Probiotic bacteria are widely occurring intestinal bacteria
and interventional studies with probiotic bacteria are
generally considered to be safe. Probiotic bacteria are
used in fermented dairy products and other foods in-
cluding some infant formulas. Moreover, there is a wide
range of commercial products available at pharmacies
and health food stores.
All strains included in Vivomixx® are known and ac-
cepted organisms in food and have been used in clinical
studies in the form of VSL#3 in obese children with
nonalcoholic steatohepatitis [27], patients with inflam-
matory bowel disease [35–37], critically ill patients [38],
patients with cirrhosis [39, 40] and pediatric patients
[41, 42] with no reported side effects.
Clinical studies on pregnant women and infants also
support the safe use of probiotics during pregnancy and
early infancy [22, 43, 44].
Participants are asked about side effects of the
product at every study visit and their answers are
recorded in the CRF.
Sample size and statistics
This is the first pilot study in which the probiotic Vivo-
mixx® is added in a randomized fashion to the standard
of care in obese pregnant women. Fifty pregnant women
are planned to be included. Data for publication of these
data will be analyzed with statistical software and signifi-
cance will be set at P < 0.05.
By a group size of 2 × 25 participants, and on the as-
sumption that probiotics reduce average GWG by 2 kg –
from 10 kg to 8 kg (SD 6.5), the study will have a strength
of 19 %. Under these assumptions the expected width of
the confidence interval will be 5.
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All continuous data results based on treatment with
Vivomixx® and placebo will be analyzed using chi-square,
and all categorical data results based on treatment with
Vivomixx® or placebo will be analyzed using t tests.
For planning of the final study the significance level
for the outcomes will be set at P < 0.1 to select the rele-
vant outcome measurements.
Discussion
In summary, previous studies in pregnant obese women
state that obesity in pregnancy is associated with adverse
outcomes for both mothers and infants, including the
risk for pregnancy-induced hypertension, preeclampsia,
GDM and macrosomia. Weight gained in pregnancy
affects the health of both the mother and her unborn
child. Most studies for the prevention of GDM and
excessive GWG among overweight and obese pregnant
women have until now been restricted to lifestyle inter-
ventions and have shown mixed results and only modest
improvements [12]. Probiotic supplementation, if benefi-
cial, would be easier to use in clinical practice. As previ-
ously mentioned, evidence exists that daily consumption
of probiotics could reduce the risk of preeclampsia [20],
maintain serum insulin levels [21] and reduce the fre-
quency of GDM [22] in pregnant women. These trials
used different probiotic strains, and it is a general as-
sumption that different kinds of probiotics influence the
microbiota differently and thereby have varying effects
on metabolic functions. The study by Luoto et al. in
2010 was a randomized controlled trial of probiotic
intervention with capsules containing Lactobacillus
rhamnosus GG and Bifidobacterium lactis BB12 in 256
normal-weight pregnant women and reported a reduced
risk of GDM from 34 to 13 % (P = 0.003) with a com-
bined dietary/probiotic supplementation [22]. Two other
studies have examined the effect of probiotic milk prod-
ucts. The study by Asemi et al. in 2013 was a random-
ized controlled trial including 70 pregnant women in
their third trimester who were randomly assigned to
consume 200 g per day of conventional or probiotic yog-
hurt containing two strains of lactobacilli (L. acidophilus
LA5) and bifidobacteria (Bifidobacterium animalis
BB12) for 9 weeks. Significant differences were found in
serum insulin levels: +1.2 ± 1.2 versus +5.0 ± 1.1 μIU/ml
(P = 0.02), and the conclusion was that the consumption
of probiotic yoghurt maintains serum insulin levels and
might help prevent developing insulin resistance during
pregnancy [21]. Brantsæter et al. in 2011 studied a co-
hort of 33,399 primiparous women where milk-based
products containing probiotic lactobacilli (L. acidophilus
LA5, B. lactis BB12, L. rhamnosus GG) were estimated
from a self-reported FFQ. Adjusted for confounders, in-
take of probiotic products during pregnancy was associ-
ated only with reduced risk of severe preeclampsia (odds
ratio = 0.79, 95 % confidence interval 0.66, 0.96) [20].
Only one double-blind, placebo-controlled, randomized
study, using probiotics in 175 pregnant obese women
has so far been carried out but showed no effects on
either maternal fasting glucose, metabolic profile or
pregnancy outcomes after 4-week probiotic treatment
(Lactobacillus salivarius UCC118) between gestational
weeks 24 and 28 [45]. The duration of the intervention
could influence the outcomes of the studies, and 4 weeks
is possibly too short a period to induce significant
changes as infants receive their first microbial flora at
the time of delivery. These inoculated bacteria reflect
the microbiota of the mother’s vagina and gastrointes-
tinal tract and influence further intestinal microbiota de-
velopment [46]. The gut microbiotas of infants are
dynamic and highly dependent on a number of factors
including delivery method and diet (for example, breast-
feeding versus formula-feeding) [47]. Differences in the
initial microbiota, e.g. gut microbiota associated with
overweight or excessive weight gain, can alter the devel-
opmental pathways of the infant’s microbiota, which
could have important implications for infant develop-
ment and health [48]. A recently published systematic
review of studies that reported on the effects on mater-
nal outcomes of probiotic treatment in pregnant women
highlighted the need for studies involving obese women
because of their increased risk of adverse pregnancy out-
comes [49]. Also a review by Barrett et al. in 2014 [50]
on probiotics for preventing GDM concluded that there
is a requirement for further studies – especially in popu-
lations with higher risks of developing GDM. Because
maternal obesity is highly prevalent worldwide and asso-
ciated with adverse outcomes for both mothers and
infants, it is important to develop new treatment
methods to prevent these adverse outcomes. Intrauterine
life and early infancy are critical stages for targeting in-
terventions aiming to reduce the risk of overweight
development in future generations. We hypothesize that
changing the microbial environment of the mother and
her fetus can modify the health of the child. The findings
of this study should advance current knowledge in this
field in terms of weight management interventions for
obese pregnant women, as well as the influence of pro-
biotics on pregnancy and on the child’s health. In sum-
mary, we expect that our findings will demonstrate that
Vivomixx® can alter gut microbiota in obese pregnant
women and thereby reduce the risk of developing preg-
nancy and birth complications. We anticipate that re-
sults from this trial may have implications for the future
treatment of obese pregnant women. The intervention
could result in fewer obese children, with significant im-
portance for the individual child healthwise, psychologic-
ally and socially. The results will also form the basis for
future research to ensure healthy mothers and children.
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Results from this pilot study will provide data to fa-
cilitate planning for a definitive study investigating the
effects of Vivomixx® in pregnant obese women and
their newborn.
Trial status
This pilot study started enrolling in March 2015. Cur-
rently, 20 participants have been included in the study
(November 2015).
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